Skip to search formSkip to main contentSkip to account menu

vabicaserin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A series of pyrido[3,4-d]azepines that are potent and selective 5-HT2C receptor agonists is disclosed. Compound 7 (PF-04781340… 
2014
2014
A quantitative systems pharmacology model that combines in vitro/preclinical neurophysiology data, human imaging data, and… 
2013
2013
An efficient, asymmetric synthesis of the 5-HT2C agonist vabicaserin in four chemical steps and 54% overall yield from… 
2011
2011
Vabicaserin has been developed for the treatment of schizophrenia. It was evaluated in this randomized, double- blind, placebo… 
2010
2010
Vabicaserin is a potent 5-hydroxytryptamine2C agonist that is currently being developed for the treatment of the psychotic… 
2008
2008
The American Diabetes Association has determined that diabetes costs the United States more than $170 billion per year in…